Abstract: In one embodiment, the ESD device uses highly doped P and N regions deep within the ESD device to form a zener diode that has a controlled breakdown voltage.

Abstract: In one embodiment, the ESD device uses highly doped P and N regions deep within the ESD device to form a zener diode that has a controlled breakdown voltage.

Abstract: A semiconductor component resistant to the formation of a parasitic bipolar transistor and a method for manufacturing the semiconductor component using a reduced number of masking steps. A semiconductor material of N-type conductivity having a region of P-type conductivity is provided. A doped region of N-type conductivity is formed in the region of P-type conductivity. Trenches are formed in a semiconductor material and extend through the regions of N-type and P-type conductivities. A field oxide is formed from the semiconductor material such that portions of the trenches extend under the field oxide. The field oxide serves as an implant mask in the formation of source regions. Body contact regions are formed from the semiconductor material and an electrical conductor is formed in contact with the source and body regions. An electrical conductor is formed in contact with the backside of the semiconductor material.

Abstract: A speaker device for improving mid/high-range frequencies includes a magnetic base, a frame annularly mounted to the magnetic base, a cone mounted to an inner side of the frame, a voice coil mounted to the cone and suspended in a gap of the magnetic base, and a deadening phase plug mounted on a central portion of the magnetic base. The magnetic base includes a T-iron, a magnet, and a pole plate. The deadening phase plug is made of a sound-absorbing material for absorbing and eliminating sound waves generated by the voice coil and the cone.

Abstract: Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

Abstract: Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

Abstract: A speaker device for improving mid/high-range frequencies includes a magnetic base, a frame annularly mounted to the magnetic base, a cone mounted to an inner side of the frame, a voice coil mounted to the cone and suspended in a gap of the magnetic base, and a deadening phase plug mounted on a central portion of the magnetic base. The magnetic base includes a T-iron, a magnet, and a pole plate. The deadening phase plug is made of a sound-absorbing material for absorbing and eliminating sound waves generated by the voice coil and the cone.

Abstract: Quinoline and quinoxaline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

Abstract: An integrated circuit memory device has an array of memory cells arranged in a plurality of rows and columns and a plurality of row lines and a plurality of column lines. Cells arranged in the same row are connected by a common row line, and cells arranged in the same column are connected by a common column line. Each cell in the array is addressed by an address signal which has a plurality of bits. A sense amplifier circuit is connectable to one or more of the plurality of column lines of the array. An address input terminal receives in series the plurality of bits of the address signal. Each of the column lines is connectable to a pre-charge voltage, in response to a read command.

Abstract: An integrated circuit memory device has a plurality of memory cells arranged in a plurality of arrays. Each array has a plurality of rows, and a plurality of column lines, and a plurality of row lines connecting to the memory cells in each array. The memory cell in an array is addressable by a column line and a row line. A column address decoder receives a column address signal and selects one or more column lines of each array in response. A row address decoder receives a row address signal and selects a row line of each array in response. The memory device also has a plurality (k) of sense amplifiers, with one sense amplifier associated with each array, connectable to one or more column lines of the array and receives a signal therefrom supplied from an addressed memory cell. The memory device further has a register; and a control circuit.

Abstract: PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

Abstract: PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

Abstract: The present invention provides inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion having Formula (I) which are useful for the treatment of obesity and related diseases, as well as prevention and treatment of atherosclerosis and its clinical sequelae, for lowering serum lipids, and in the prevention and treatment of related diseases. The invention further relates to pharmaceutical compositions comprising the compounds of the present invention and to methods of treating obesity, atherosclerosis, and related diseases and/or conditions with the compounds of the present invention, either alone or in combination with other medicaments, including lipid-lowering agents.

Abstract: A speaker includes a T-shape iron, a ring magnet, a pole plate, a frame, a diaphragm, a coil core portion, a voice coil, a first annular corrugated plate, and at least one second annular corrugated plate. The second annular corrugated plate has is bonded to an inner side or an outer side of an outer section of the first annular corrugated plate and spaced from the coil core portion, thereby increasing a thickness and strength of an outer section of the first annular corrugated plate for bearing higher power such that the speaker generates clear sound and that an inner section of the first annular corrugated plate generates sufficient sound pressure when a power outputted by the speaker is low.

Abstract: This invention relates to mutual prodrugs of amlodipine and atorvastatin and to pharmaceutical compositions thereof. This invention also relates to methods of treating angina pectoris, atherosclerosis, and hypertension and hyperlipidemia in a mammal using those prodrugs and compositions. This invention also relates to methods of managing cardiac risk in a mammal, including humans, presenting with symptoms of cardiac risk by administering those prodrugs and compositions.

Abstract: This invention relates to a mutual salt of amlodipine and atorvastatin, pharmaceutical compositions thereof and methods of treating angina pectoris, atherosclerosis and combined hypertension and hyperlipidemia in mammals with such a mutual salt and compositions. This invention also relates to methods of managing cardiac risk in a mammal presenting with symptoms of cardiac risk, including humans by administering such a mutual salt and compositions.

Abstract: A terminal connection mechanism used in an electroluminescent display structure primarily comprises a display panel housed in a decorative case and a terminal portion provided on the lower end of the display panel to receive a connector affixed by electrical conductive wires. The connector is provided on one side wall face thereof with a resilient locating plate that enables the connector to be detachably secured in position in the case. Thus the terminal connection mechanism according to the invention can provide an electroluminescent display the convenience in connection and separation between a display panel and its electrical conductive wires. It has practical value in industry.

Abstract: The general method involves contacting a bacterial colony with a .beta.-D-galactosidase substrate and a carbon source metabolizable by a plurality of coliform species but not metabolizable by E. coli, and detecting reaction product signals of the substrate and carbon source. Typically, the carbon source is a carbohydrate, preferably adonitol, esculin, salicin, amygdalin, or cellobiose. The absence of both reaction product signals indicates the presence of non-coliform bacteria; the presence of both reaction product signals indicates the presence of non-E. coli coliform bacteria; and, the presence of the .beta.-D-galactosidase substrate reaction product signal and absence of the carbon source reaction product signal indicates the presence of E. coli.A signal may identify a reaction product itself (e.g. a colored product derived from a chromogenic form of the substrate or from a chromogenic reagent which interacts with the product, etc.), or an effect of a reaction product on or at the colony (e.g.

Abstract: This invention is directed to compounds of formula (I) or the stereoisomers, pharmaceutically acceptable salts and hydrates thereof. The compounds are Apo B/MTP inhibitors and are useful in the treatment of various disorders and conditions such as atherosclerosis, pancreatitis, obesity, hypercholesteremia, hypertriglyceridemia, hyperlipidemia, and diabetes. The compounds of this invention are also useful in combination with other pharmaceutical agents including cholesterol biosynthesis inhibitors and cholesterol absorption inhibitors,especially HMG-CoA reductase inhibitors and HMG-CoA synthase inhibitors; HMG-CoA reductase gene expression inhibitors; CETP inhibitors; bile acid sequestrants; fibrates; cholesterol absorption inhibitors; ACAT inhibitors, squalene synthetase inhibitors, ion-exchange resins, anti-oxidants and niacin.

Abstract: A hydrochloride salt of an Apo B secretion/MTP inhibitor, methods of making the salt, methods of using the salt and pharmaceutical compositions containing the salt are disclosed.